| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Redhill Biopharma Ltd. | YELIVA (Opaganib) | COVID-19 | Phase 2/3 | Ongoing | Oral | COVID-19 |
| Redhill Biopharma Ltd. | RHB-102 | GLP-1/GIP receptor agonist therapy-associated GI side effects | Phase 2 | Trial Planned | Oral | Endocrinology |
| Redhill Biopharma Ltd. | Opaganib (ABC294640) | Neuroblastoma | Phase 2 | Ongoing | Oral | Oncology |
| Redhill Biopharma Ltd. | RHB-107 (upamostat) - (ACESO PROTECT) | Early COVID-19 outpatient treatment | Phase 2 | Ongoing | Oral | COVID-19 |
| Redhill Biopharma Ltd. | Opaganib - (MUSC Trial) | Prostate Cancer | Phase 2 | Ongoing | Oral | Oncology |
| Redhill Biopharma Ltd. | BEKINDA | IBS-D | Phase 2 | Trial Planned | Oral | Gastroenterology |
| Redhill Biopharma Ltd. | YELIVA (Opaganib) | COVID-19 | Phase 2a | Trial Completed | Oral | COVID-19 |
| Redhill Biopharma Ltd. | YELIVA (Opaganib) | Cholangiocarcinoma | Phase 2a | Ongoing | Oral | Oncology |